Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

MYCOF Relative to the S&P 500

MYCOF Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Mydecine Innovations Group Inc. (OTCMKT:MYCOF) seasonal charts above shows that a Buy Date of June 18 and a Sell Date of October 12 has resulted in a geometric average return of 11.78% above the benchmark rate of the S&P 500 Total Return Index over the past 9 years. This seasonal timeframe has shown positive results compared to the benchmark in 5 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 9 years by an average of 111.78% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 9 years of data is available for shares of MYCOF, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

To download MYCOF seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: MYCOF